BHRF1, a component of the restricted early antigen (EA) complex of the Epstein-Barr virus (EBV) lytic cycle, encodes a 17 kDa putative transmembrane protein with both sequence and functional homology to the Bcl-2 proto-oncogene. To determine whether there was any sequence variation over the BHRF1 open reading frame (ORF), 15 EBV isolates from different geographical regions and from both healthy donors and patients with EBV-associated diseases were sequenced. A small number of base changes which resulted in amino acid substitutions in the BHRF1 protein were found relative to the prototype B95.8 EBV sequence and these were predominantly clustered near the amino terminus of the BHRF1 protein outside conserved domains identified in the Bcl-2 homologues. In transient transfection assays none of the mutations in the BHRF1 ORF from eight different EBV isolates had a
Introduction
Epstein-Barr virus (EBV), a ubiquitous human herpesvirus with oncogenic potential, is predominantly associated with infection of two target tissues in vivo : B lymphocytes, where the infection is largely non-productive, and stratified squamous epithelium, in which virus replication occurs (Rickinson & Kieff, 1996) . Both these cell types are susceptible to EBVassociated transformation resulting in tumours of B cell origin (Burkitt's lymphoma, immunoblastic lymphoma) or of epithelial cell origin (nasopharyngeal carcinoma, gastric adenocarcinomas) (Thomas et al., 1991 ; Magrath et al., 1992 ; Osato & Imai, 1996 ; Rickinson & Kieff, 1996) . Whilst Whilst all eight EBV isolates and E1B-19K gave comparable levels of protection to the DNA-damaging agent cis-platin, Bcl-2 did not afford significant protection. Thus, despite several amino acid changes in the BHRF1 ORF of some of the EBV isolates studied, the ability of the protein to protect against cis-platin induced apoptosis is conserved. The highly conserved nature of BHRF1 amongst different EBV isolates at both the sequence and functional level supports the proposed important role of BHRF1 in delaying cell death, thereby maximizing the production of progeny virus and facilitating the establishment of virus persistence. the expression of EBV latent genes is strongly implicated in the development of these malignancies, it is also possible that viral proteins involved in EBV replication may influence the oncogenic process. In this respect BHRF1, an immediate early EBV antigen with sequence homology to Bcl-2, is of particular interest (Pearson et al., 1987) . Although dispensable for both virus-induced cell growth transformation in vitro and virus replication (Marchini et al., 1991 ; Lee & Yates, 1992) , BHRF1 has a proven ability to act as a cell survival gene. EBV-negative BL cells expressing BHRF1 are rendered more resistant to programmed cell death (apoptosis) under experimental conditions of growth factor withdrawal and rodent hamster fibroblasts expressing BHRF1 display increased resistance to the apoptotic inducing effects of DNA-damaging drugs (Henderson et al., 1993 ; Tarodi et al., 1994) . These studies suggest that whilst BHRF1 is not consistently expressed in F. Khanim and others F. Khanim and others EBV-associated tumours, it is possible that expression of this protein at an early stage in the oncogenic process may influence the development of these malignancies. To date, the only in vivo lesion where BHRF1 is abundantly expressed is oral ' hairy ' leukoplakia (HL), a benign lesion of oral tongue mucosa which represents a focus of chronic EBV replication with absence of detectable latent gene expression (Greenspan et al., 1985 ; Gilligan et al., 1990 ; Niedobitek et al., 1991 ; Young et al., 1991) . Our recent data demonstrating that BHRF1 can delay the terminal differentiation of epithelial cells through the prevention of apoptosis suggests that this protein may be responsible for HL pathology but may normally function to delay cell death during EBV replication so that full virus maturation can occur (Dawson et al., 1995) .
The anti-apoptotic properties of BHRF1 are similar to those of Bcl-2, suggesting that the sequence homology between these proteins is also reflected at the functional level. With the identification of additional cellular genes homologous to Bcl-2 (i.e. Bcl-x, Bax, Bak, Bad etc.), all of which are involved in the regulation of apoptosis, it seems that BHRF1 is one member of an ever-expanding group of Bcl-2 homologues (Boise et al., 1993 ; Oltvai et al., 1993 ; Boyd et al., 1995 ; White, 1996) . BHRF1 belongs to an increasing family of viral proteins with sequence and functional homology to Bcl-2 including the adenovirus E1B 19K protein and the recently described ORF16 gene of Kaposi's sarcoma herpesvirus (Boyd et al., 1994 ; White, 1996 ; Sarid et al., 1997 ; Young et al., 1997) . Amongst this family of genes, the principle regions of homology are clustered within two motifs referred to as Bcl-2 homology domains 1 and 2 (BH1 and BH2). More specifically, the amino acid (aa) residues Gly-145 in BH1 and Trp-188 in BH2 (Bcl-2 coordinates) have been demonstrated to be essential for the anti-apoptotic function of Bcl-2 and its ability to heterodimerize with Bax (Yin et al., 1994) . Outside of BH1 and BH2, three further conserved homology domains have been identified. NH1 and NH2 were identified by sequence comparison with the adenovirus E1B 19K protein and the Bcl-2 sequence . Domain swapping studies between the NH1 homology domain of adenovirus E1B-19K protein and Bcl-2 have shown complementation of function. Analysis of Bik, another Bcl-2 homologue, has identified another domain, adjacent to NH1, referred to as BH3, which is present only in cell death-inducing proteins such as Bax and Bak and mediates the interaction of Bax with E1B-19K and Bcl-2 proteins Han et al., 1996) . An interaction between the cell death-inducing protein Bik and the cell deathsuppressing proteins BHRF1 and E1B-19K has been demonstrated . Recent work indicates that BHRF1 does not heterodimerize with Bax but can interact with p23 RRas (Theodorakis et al., 1996) , a member of the Ras superfamily that has previously been shown to interact with Bcl-2 (Fernandez-Sarabia & Bischoff, 1993 ; Wang et al., 1995) . Specific mutations in BHRF1 which abrogate the interaction with R-Ras confer a proliferative capacity on BHRF1 (Theodorakis et al., 1996) . Thus, it was suggested that the R-Ras interaction normally acts to restrain this proliferative effect of BHRF1 and that mutations in BHRF1 which prevent R-Ras binding may contribute to the pathogenesis of EBV-associated tumours.
Assuming that the function of BHRF1 also requires heterodimerization with other members of the Bcl-2 family, we sought to determine the degree of BHRF1 sequence variation among EBV isolates of both B cell and epithelial cell origin, especially over the conserved homology domains and over the R-Ras binding region. EBV strains can be broadly classified as type 1 or type 2 on the basis of allelic polymorphism of the virus-encoded EBNA2 and EBNA3 nuclear antigens (Young et al., 1987 ; Sample et al., 1990 ; Kieff, 1996) , but other minor differences identified by restriction enzyme fragment length polymorphisms (RFLP) have also been found in geographically distinct EBV isolates (Lung et al., 1991 ; Abdel-Hamid et al., 1992 ; Khanim et al., 1996) . Thus, we analysed BHRF1 sequence variation in both type 1 and type 2 viruses and in EBV isolates obtained from donors of different geographical origin with particular interest in the specific regions of BHRF1 which either have homology with Bcl-2 or mediate the interaction with RRas. Functional assays were performed to identify any aa mutations which altered the ability of the BHRF1 protein to protect against apoptosis induced by the DNA-damaging agent cis-platin.
Methods
EBV isolates. All of the EBV isolates used in the study were classified as type 1 or type 2 using PCR across the EBNA2 and EBNA3C genes as described previously (data not shown) (Sample et al., 1990) . The range of EBV isolates sequenced in this study is detailed in Table 1 . The samples include EBV isolates from NPC, HL, BL and also normal donors from different geographical regions.
DNA extraction and amplification of the BHRF1 ORF. The BHRF1 ORF was amplified from each isolate with the external primer combination of BH1A (coordinates 54334-54353 : 5h GTTCCCTCTTA-ATTACATTT 3h) and BH1B (coordinates 55012-54993 : 5h CAATGA-CCCTGATTCATATA 3h), positioned just outside the BHRF1 open reading frame (ORF) (co-ordinates 54376-54948). Sequence coordinates correspond to the published B95.8 sequence of Baer et al. (1984) . DNA was extracted and PCR performed as described previously (Sample et al., 1990 ; Maunders et al., 1994) . The 660 bp PCR products were agarose gel purified (Wizard PCR Preps Kit, Promega) and cycle sequenced (AmpliTaq cycle sequencing kit, Perkin-Elmer Cetus) according to the manufacturer's instructions with 5h-$#P end-labelled internal primers BH1C (5h AAATCCAGATCCACATGTTC 3h), BH1D (5h ATAGATT-AGTGTCTTCCTCTGG 3h), BHIE (5h GCTTGAGGAGATAATTGA-AC 3h) and also BHIA. The sequence data were analysed using the Genetics Computer Group (GCG) package (version 8, September 1994) for variation in aa sequences. All oligonucleotide primers were synthesized by Alta Bioscience (University of Birmingham, Birmingham, UK).
Cloning of the BHRF1 ORFs, E1B-19K ORF and Bcl-2 ORF into pSG5. PCR primers incorporating restriction enzyme recognition sequences for cloning of BHRF1 and 19K PCR products were designed and DNA amplified from the isolates as described above. BH1B-BglII, 5h The EBV isolates were sequenced across their BHRF1 ORFs. EBV type was determined by DNA PCR across the EBNA2 and EBNA3C genes using well-characterized primers (data not shown ; Sample et al., 1990 GCAGAGATCTCAATGACCCTGATTCATA 3h (Bgl II site) was used in combination with BH1A to amplify the BHRF1 ORF. An internal Bgl II site present between the BH1A primer and the BHRF1 ORF was used in combination with BH1B-BglII for cloning into the polylinker of the eukaryotic expression vector pSG5 (Stratagene). The adenovirus 12 E1B-19K ORF was amplified from the pMac10.3 19K expression vector (kindly provided by Julian Parkhill) with the primers EcoRI-19K 5h GCAGGAATTCATCTTAGTAATGGAGTTGGA 3h (EcoRI site) and BamHI-19K 5h GCAGGGTACCGTTCCATGTTTACTTCTCCA 3h (BamHI site). Following gel purification (Qiaex gel extraction kit, Qiagen), the PCR fragments were digested with appropriate restriction enzymes and ligated into the polylinker of the pSG5 expression vector. pSG5-Bcl2 was cloned by ligating the EcoRI fragment carrying the Bcl-2 ORF from pC∆J-Bcl-2 (Tsujimoto, 1989) into the EcoRI site in pSG5. Plasmid DNA from positive E. coli colonies (XL1-Blue, Stratagene) was extracted and sequenced to confirm the integrity of the cloned sequence before the preparation of caesium chloride gradient purified plasmid DNA (Sambrook et al., 1989) for transfections.
Generation of BH1 and BH2 mutants of BHRF1. Mutations in the BH1 and BH2 domains of BHRF1 were generated by PCR sitedirected mutagenesis using the overlap extension method of Ho et al. (1989) . For each mutation this initially involved two separate PCR reactions on B95.8 EcoRI A using primers containing the desired mutations in top and bottom strands and primers external to the BHRF1 sequence. The two PCR products were denatured, hybridized and a third PCR reaction used with primers just outside the BHRF1 gene. Inclusion of an EcoRI site in one primer and a Bgl II site in the other allowed the final PCR product to be cleaved with EcoRI and Bgl II and cloned directly into the appropriate sites in pSG5. Sequencing confirmed the desired mutation. In the BH1 mutant (m2) this procedure results in the Phe at aa 91 and the Gly-Arg at aa 99 and 100 of BHRF1 being replaced with Ala ; the GlyArg are conserved between BHRF1, Bcl-2 and E1B-19K and the Gly-99 corresponds with the functionally important Gly-145 in Bcl-2. In the BH2 mutant (m5) this results in the Trp at aa 143 and 150 and the Gly at 149 being replaced with Ala ; the two Trp and Gly are conserved between BHRF1, Bcl-2 and E1B 19K and the Trp-143 corresponds with the functionally important Trp-188 in Bcl-2.
Cell lines. Cos-1 cells were maintained in RPMI 1640 (Gibco-BRL) supplemented with 8 % foetal calf serum (FCS), 4 mM -glutamine, 50 units\ml penicillin and 50 µg\ml streptomycin. SVK cells, an SV40 large T antigen transformed keratinocyte cell line (a gift from P. H. Gallimore), were maintained in Joklics medium supplemented with 8 % FCS, 4 mM -glutamine, 50 units\ml penicillin, 50 µg\ml streptomycin, 0n4 µg\ml hydrocortisone and 10 ng\ml cholera toxin (Li et al., 1992) . Transient transfections were performed on cells maintained as exponentially growing cultures.
Transient transfections.
Caesium chloride gradient purified plasmid DNA was transfected into Cos-1 cells by the modified DEAEdextran method of Gonzalez & Joly (1995) . Briefly, 10' Cos-1 cells or 1n5i10' SVK cells were incubated at 37 mC for 2 h in an airtight 25 cm$ T25 tissue culture flask containing 3 ml of the transfection cocktail (100 µM chloroquine, 10 µg plasmid DNA and 100 mM DEAE-dextran in DME). After several washes in warm PBS the cells were shocked for 2 min with 10 % dimethyl sulphoxide (DMSO) in PBS and, after a further two washes with PBS, returned to complete growth medium and allowed to recover overnight. Twenty-four hours after transfection, the cells were recovered by trypsinization and plated out into 96-well plates for MTT assays or onto slides for immunofluorescence studies. Cells for immunoblotting were grown for 72 h after transfection in the same culture flasks prior to harvesting.
Immunoblotting for transfected proteins. Seventy-two hours post-transfection, cells were trypsinized, solubilized and 20 µg total protein separated by Laemmli SDS-PAGE before electroblotting onto nitrocellulose filters as described previously (Henderson et al., 1991 ; Maunders et al., 1994) . Membranes were blocked with blocking buffer (5 % skimmed milk in PBS) for 1 h, incubated in primary antibody diluted in blocking buffer for 1 h then washed with PBS-0n1 % Tween 20. BHRF1 protein was detected with a 1 : 2000 dilution of rabbit polyclonal serum (gift from Marie Hardwick ; Murray et al., 1996) or 1\1000 BHRF1-specific 5B11 mouse monoclonal antibody (MAb) (Pearson et al., 1987) . E1B-19K was detected with 1 : 2000 dilution of a rat tumour bearer serum (kindly provided by R. Grand, CRC Institute for Cancer Studies, Birmingham, UK) and Bcl-2 detected using a 1 : 20 dilution of anti-Bcl-2 mouse MAb 124 (Dako). Membranes were washed with PBS-0n1% Tween 20, incubated with 1 : 1000 dilutions of horseradish peroxidaseconjugated secondary antibodies for a further hour and signal developed by chemiluminescence (ECL detection kit, Amersham) and detected by autoradiography.
Immunofluorescence staining. Protein localization was analysed by immunofluorescence staining of cells grown on slides. Twenty-four hours after transfection, transfected cells were trypsinized, counted, and plated onto sterile microdot slides (Hendley-Essex) at 10% cells per well. After a further 48 h incubation at 37 mC, the slides were washed with PBS, fixed in 4 % paraformaldehyde and permeabilized in ice-cold acetone. After fixing, the wells were incubated with the relevant primary antibody diluted in PBS containing 20 % heat inactivated normal goat serum (HINGS) for 1 h at 37 mC. These included the BHRF1 specific mouse MAb, 5B11 (Virotech International), the Bcl-2 specific mouse MAb, PAB124 (Dako) and an antibody specific for adenovirus 12 E1B-19K protein (a gift from R. J. Grand). After three washes in PBS, slides were incubated with fluorescein isothiocyanate (FITC)-conjugated secondary antibodies (diluted to 1 : 50 in 20 % HINGS) for a further hour at 37 mC before washing with PBS and mounting in DABCO (1,4-diazobicyclo[2,2,2]octane). Immunofluorescence images were captured on a Zeiss Axioscopic microscope using the Biovision Confocal microscope software from Improvision. Raw image data were processed with the Improvision Openlab V1.3 package and images montaged and annotated in Adobe Photoshop 3.0.
Cis-platin and MTT assays. Twenty-four hours post-transfection, cells were trypsinized and plated at 1i10% cells per well in 96-well plates. Cis-platin at 1 to 1000 µM final concentration in growth medium (containing 2 % FCS) was added to triplicate wells at each concentration and plates incubated at 37 mC for a further 72 h. Control wells containing no cis-platin were included in each 96-well plate. Cell survival was BHRF1 in different EBV isolates BHRF1 in different EBV isolates determined by MTT assay as described previously (Dawson et al., 1995) and survival of cells incubated in cis-platin calculated as percentages relative to untreated cells.
Results

Sequence variation in the BHRF1 ORF
The results of sequencing the BHRF1 ORF from 15 different EBV isolates are summarized in Fig. 1 (A) , which shows the nucleotide (nt) changes, and in Fig. 1 (B) , which shows the aa changes detected in the various EBV isolates relative to the known Bcl-2 homology domains. All of the amino acid changes detected in the isolates fell outside of all known Bcl-2 functional domains. The BHRF1 ORF of the type 2 EBV (B) Fig. 1 . Sequence changes detected in the BHRF1 ORF of different EBV isolates. The BHRF1 ORF from 15 EBV isolates was amplified from total DNA extracted from each sample and cycle sequenced. (A) Summary of all the conservative nt changes detected. The top line of each pair of sequences is nt sequence of EBV from this region starting at B95.8 coordinate 54359 and is 615 bp long. The BHRF1 ORF is identified by bold letters and the corresponding aa sequence is shown below the nt sequence. aa and nt co-ordinates are given at the left-hand side of the sequences. Conservative nt changes and the EBV isolates in which they were found are shown below the sequence. (B) Summary of the non-conservative nt substitutions and the corresponding aa changes detected in the BHRF1 from the different EBV isolates sequenced. The BHRF1 aa sequence listed in the box corresponds to the B95.8 sequence and the positions of all known Bcl-2 homology domains are shown in shaded boxes. Gly-99 in BH1 corresponds to the functionally important Gly-145 in Bcl-2 and Trp-143 corresponds to the functionally important Trp-188 in Bcl-2 (Yin et al., 1994) . The black arrows represent the alanine substitutions made in BH1 or BH2 to generate the BHRF1 mutants used in the functional studies. The 50-1 BHRF1 proliferation conferring mutation of Theodorakis et al. (1996) is identified by the black underlined residues, YH.
isolate AG876 was identical to that of the type 1 B95.8 strain, except for a T C conservative nt change in AG876 at position 54638 which was also present in all other isolates analysed indicating a divergence in the B95.8 sequence. Thus, when compared with the AG876 sequence, complete conservation of the BHRF1 ORF was found in WW1-BL (New Guinea, type 1), Gor-BL (New Guinea, type 2), D5 (Chinese, type 1) and HL1085 (Caucasian, type 2). The BHRF1 ORF from the EBV isolate carried by the healthy South-East Asian donor DH had three conservative nt changes (Fig. 1 A) , two of which were also present in the Chinese NPC biopsy-derived EBV isolate, NPC135. Conservative nt changes in the BHRF1 ORF from EBV isolates present in HL144 and HL512 were also CJJB F. Khanim and others F. Khanim and others identified (Fig. 1 A) . Conservative nt changes were also detected in WW2-BL, C15, H17-BL and L2-STL. The remainder of the nt changes detected in the BHRF1 ORF in the EBV isolates sequenced resulted in aa changes ( Fig.  1 A, B) . Amongst the South-East Asian isolates, the two LCLs from NPC patients (CKL and YKO) had an identical nt change resulting in a Leu Val conservative aa change at position 88 which is not present in the LCLs from the two healthy donors, D5 and DH. Two additional nt changes in the isolate from donor DH gave rise to a His Pro at aa position 75 and a Val Leu change at aa position 79. Interestingly, this latter aa change was also observed in NPC135 and in the New Guinea EBV isolates from WW2-BL, L2-STL and H17-BL. An Arg His change was observed at aa position 39 in the C15 isolate as a result of a G A nt change. Both WW2-BL and H17 had identical aa mutations at positions 38 and 78 in the amino terminus of BHRF1 as well as changes at aa positions 120 and 156 in the carboxy terminus. Of the HL biopsies, all the type captured on the Biovision confocal microscope, raw data processed in Improvision Openlab and images montaged in the Adobe Photoshop graphics program. The control pSG5 (A) and B95.8-BHRF1 (D), C15-BHRF1 (E) and L2-BHRF1 (F) transfected SVK cells were stained with the anti-BHRF1 MAb 5B11and the different BHRF1 isolates gave similar patterns of staining. Bcl-2 expression (B) was detected with the anti-Bcl-2 MAb 124 and showed distinct localization differences compared to BHRF1. E1B-19K expression (C) was detected using a rat tumour bearer serum. Similar patterns of immunofluorescence staining were obtained with Cos-1 cells transiently transfected with the different expression plasmids (data not shown).
1 strains had a G T nt change in the BHRF1 ORF giving rise to an Ala Ser aa change at position 33.
The results from the sequencing study identified some conservative nt changes and some aa changes in the isolates sequenced but the BHRF1 ORF from the different isolates was generally well conserved. A point to note is that all the aa changes detected fell outside of all known Bcl2 homology domains, indicating the functional importance of these regions.
Cloning and expression of BHRF1, E1B-19K and Bcl-2
The functional effect of some of the aa changes detected was determined by cloning a selection of BHRF1 ORFs from eight EBV isolates, B95.8, DH-STL, C15, NPC135, L2-STL, WW2-BL, HL144 and HL1085, into the pSG5 eukaryotic expression vector. These EBV isolates were selected as representative isolates from the various geographical locations looked at in this study. As controls, the adenovirus 12 E1B-CJJD F. Khanim and others F. Khanim and others 19K ORF and Bcl-2 ORF were also cloned into pSG5. Transient transfection of Cos-1 cells or SVK cells with plasmid DNA routinely yielded 40-70 % transfection efficiency as observed by immunofluorescence (data not shown). Transactivation of the pSG5 SV40 immediate early promoter by the SV40 transactivating protein large T antigen present in Cos-1 and SVK cells resulted in very high levels of expression of BHRF1, Bcl-2 and E1B-19K which were easily detected by immunofluorescence (Fig. 2) and by immunoblotting (Fig. 3) .
Immunofluorescence staining of cells transiently expressing the BHRF1 protein identified a pattern of localization that was distinct from that of both Bcl-2 and the E1B-19K protein.
Although a significant proportion of BHRF1 protein localized to the mitochondria, strong staining was also observed in the perinuclear region of the cell (Fig. 2 D, E, F) , with weaker more diffuse staining of the endoplasmic reticulum. In all cases, the pattern of localization between the eight different EBV isolates appeared very similar (Fig. 2 D, E, F) . The organellar localization of BHRF1 from the different EBV isolates was confirmed by confocal microscopy (data not shown).
Whilst over-expression of BHRF1 in Cos-1 and SVK cells may influence its pattern of localization, it is interesting that transient expression of Bcl-2 and E1B-19K in these cells resulted in a pattern of staining that was clearly distinct from that obtained for BHRF1 (Fig. 2) . Bcl-2 showed a more diffuse pattern of granular staining throughout the cytoplasm which, (Fig. 1 B) to cis-platin relative to untreated cells was determined as for Fig.  4 . The data are representative of at least three independent experiments and the values presented are the means of triplicate determinations. Standard errors were less than 10 % at each point and have not been shown.
in certain cases, extended into the nucleus (Fig. 2 B) . This pattern of localization was confirmed by confocal microscopy (data not shown). The E1B-19K protein localized in a manner more similar to Bcl-2 than BHRF1 with granular staining over the whole of some cells and with some cells displaying a vesicular pattern of staining as previously described (Boyd et al., 1994) .
Immunoblotting for BHRF1, 19K and Bcl-2 showed very high levels of expression in the transfected Cos-1 and SVK cells. Fig. 4 displays the results from transient transfections in Cos-1 cells. Whilst abundant BHRF1 was detected in the transient transfections, no signal could be observed in protein samples from lytic B95.8 cells or in SCC12F epithelial cells stably transfected with BHRF1 despite lengthy exposure times. However, the low levels of BHRF1 protein expressed in the SCC12F clones are detectable by immunoprecipitation and have been shown to result in significant phenotypic effects (Dawson et al., 1995) . It was observed during immunoblotting for BHRF1 protein expression in transient transfections that the anti-BHRF1 polyclonal rabbit antiserum did not react as efficiently with the WW2-BHRF1 protein compared to all the other BHRF1 isolates (Fig. 3 A) . However, in immunofluorescent analysis with the 5B11 anti-BHRF1 MAb, WW2-BHRF1 transfectants appeared to achieve the same transfection efficiencies and also express levels of protein comparable to the other isolates. When MAb 5B11 was used in immunoblots the level of WW2-BHRF1 protein observed was comparable to that seen with the other isolates (data not shown). The apparently lower level of WW2-BHRF1 protein detected by immunoblotting using the polyclonal rabbit antiserum is explained by the fact that this antibody was raised against a peptide derived from the B95.8 BHRF1 ORF (151-STLIEDNI-PGSRRFS-165) (Murray et al., 1996) and that this sequence is altered in the WW2 BHRF1 isolate by a D N aa change at position 156 (Fig. 1) .
Immunoblotting of E1B-19K transient transfections with a rat polyclonal antiserum yielded a strong 19 kDa band similar to the E1B-19K band observed in adenovirus 12 transformed human embryonic retinoblast (Ad12-HER2s) cells (Fig. 3 B) . Confirmation of Bcl-2 protein expression by immunoblotting identified an intense 26 kDa band in transiently transfected Cos-1 cells together with additional bands (Fig. 3 C) . Control Cos-1 cells express low levels of endogenous Bcl-2 which is markedly increased after transient transfection (Fig. 3 C) . Upon longer exposure of the gels, the additional Bcl-2 specific bands observed after transient transfection were also detected in X50\7 cells and in cell lines transfected stably with the Bcl-2 expression vector, pC∆J-Bcl-2 (Tsujimoto, 1989 ) (data not shown).
Protection against cis-platin-induced apoptosis
To determine if there was any functional significance in the amino acid changes observed in the BHRF1 ORFs sequenced from various EBV isolates, a cis-platin sensitivity assay based on transient transfection was developed. Cos-1 cells or SVK cells transiently transfected with the BHRF1 isolates were plated out into 96-well plates and incubated with various concentrations of the cytotoxic drug cis-platin for 72 h. Survival of the cells from cis-platin-induced apoptosis was then measured by MTT assay and the results plotted as percentage survival relative to non-treated cells. Representative graphs of the protection conferred by the BHRF1 isolates on Cos-1 and CJJF F. Khanim and others F. Khanim and others SVK cells to cis-platin are shown in Fig. 4 (A, B) . All eight BHRF1 isolates gave significant protection against cis-platin as compared to vector only mock transfected controls (pSG5). Between a cis-platin concentration range of 10-100 µM, an average of 20 % greater cell survival above that of mock transfected cells was observed with the BHRF1 transfectants in both Cos-1 cells and SVK cells. All of the BHRF1 isolates appeared to function equally well in protection against cisplatin.
To confirm that the transient transfection assay was able to detect functionally impaired BHRF1 we generated mutants with alanine substitutions in either the functionally important BH1 (m2) or BH2 (m5) domains of BHRF1 (Fig. 1 B) . Transient transfection into SVK cells and subsequent exposure to cisplatin demonstrated that both the BH1 and BH2 mutants were unable to confer protection (Fig. 5) .
The adenovirus E1B-19K protein was also included in the study as another virus-derived homologue of Bcl-2 and in all the experiments performed E1B-19K conferred approximately the same degree of protection against cis-platin (around 20-30 % increase in survival) as did BHRF1 (Fig. 6 A, B) . Bcl-2 was also included in these assays as a positive control for protection against cis-platin-induced apoptosis ; however, the results obtained were unexpected. Despite similar transfection efficiencies to those of E1B-19K and BHRF1, high-level transient expression of Bcl-2 in both Cos-1 and SVK cells did not confer significant protection against cis-platin induced apoptosis (Fig. 6 A, B) .
Discussion
The results of this analysis show that the BHRF1 ORF is highly conserved between geographically distinct EBV isolates and in viruses from different EBV-associated diseases. Almost all of the aa changes and the majority of the nt changes were restricted to the amino terminus of BHRF1 with the exception of two New Guinea isolates present in BL cell lines, WW2-BL (type 2) and H17 (type 1), both of which had aa and conservative nt substitutions further into the BHRF1 ORF. Most importantly, all of the aa changes fell outside both the Bcl-2 homology domains that have been identified to date and the transmembrane domain. Thus, no significant changes were found in BHRF1 from EBV isolates associated with either malignant disease or the virus replicative HL lesion ; this latter observation supports that previously published (Horner et al., 1995) . Functional studies on eight of the EBV BHRF1 isolates which carried representative aa changes demonstrated the ability of these variant BHRF1 proteins to protect cells from cis-platin-induced apoptosis. Taken together, the sequencing and functional studies suggest that BHRF1 functions to protect cells from apoptosis in much the same way as Bcl-2, probably by interacting with other Bcl-2 family members as well as other cell proteins (Boise et al., 1993 ; Oltvai et al., 1993 ; Boyd et al., 1994 Boyd et al., , 1995 Yin et al., 1994 ; Subramanian et al., 1995 ; Wang et al., 1995) . A recent mutational analysis of BHRF1 has confirmed the functional importance of the Bcl-2 homology domains by demonstrating that the ability of BHRF1 to protect against p53-induced apoptosis in baby rat kidney (BRK) cells is abolished if any of these domains or the transmembrane domain are mutated (Theodorakis et al., 1996) . Our data analysing protection from cis-platin-induced apoptosis in a transient transfection assay confirm the functional significance of the BH1 and BH2 domains of BHRF1. Furthermore, the functional importance of these domains is further supported by our data demonstrating both sequence and functional conservation of BHRF1 from different EBV isolates.
None of the EBV isolates carried BHRF1 genes with mutations at aa residues 50 and 51 which are required for the interaction with R-Ras (Theodorakis et al., 1996) . Mutation of these residues has been shown to confer a proliferative effect on BHRF1 in BRK cells, suggesting that the interaction with RRas is responsible for mediating a balance between survival and proliferation (Theodorakis et al., 1996) . Whilst it was suggested that similar mutations in natural isolates of EBV might confer increased oncogenic potential to BHRF1, no such changes were identified in any of the EBV isolates examined in this study. However, in our previous study (Dawson et al., 1995) and in more recent work (C. Dawson, F. Khanim & L. S. Young, unpublished observations) we have observed a consistent proliferative effect of BHRF1 in several different cell lines, raising the possibility that the function of BHRF1 may be influenced by the levels of R-Ras expression in different cell types. This possibility is currently being examined. Another interesting observation in this study is the inability of transiently expressed Bcl-2 to confer a survival function. This may indicate fundamental differences in the function of BHRF1 and Bcl-2 which may be mediated by differing interactions with other Bcl-2 family members (i.e. BHRF1 does not appear to interact with Bax) as well as variable effects of BHRF1 versus Bcl-2 on cell cycle kinetics. An alternative explanation is that post-translational modification (i.e. phosphorylation), which has been shown to be important in regulating Bcl-2 function, may have a differential effect on BHRF1 .
Recent work using Bcl-2 mutants targeted to different organelle membranes of the cell stresses the importance of correct protein localization for Bcl-2 function (Zhu et al., 1996) . It was therefore important to determine if any of the aa changes in the BHRF1 isolates affected protein localization as well as function. Transient high level expression of BHRF1 isolates, E1B-19K and Bcl-2 in Cos-1 and SVK cells identified distinct localization patterns for the different proteins. Bcl-2 and E1B-19K displayed granular staining over both the cytoplasm and nucleus whereas the BHRF1 isolates showed a more restricted cytoplasmic pattern of localization with features characteristic of mitochondrial and endoplasmic reticulum distribution. This is contrary to previously published work where both BHRF1 and Bcl-2 were shown to have similar patterns of ultrastructural localization with a predominantly mitochondrial distribution (Hickish et al., 1994) . However, these studies were performed in B cell lines and no direct comparison of BHRF1 with Bcl-2 was presented. The high levels of protein expression in our system hampered the ability to localize E1B-19K or Bcl-2 to specific subcellular compartments and may have exaggerated their subcellular distribution. However, Bcl-2 has been shown to localize to mitotic nuclei in epithelial cells (Lu et al., 1994) and the staining for E1B-19K resembled that previously reported (Boyd et al., 1994) . Since none of the aa changes in the BHRF1 isolates fell in the hydrophobic transmembrane domain of the protein, it is not surprising that no difference in localization was observed between BHRF1 from the different EBV isolates.
Although BHRF1 is not essential for EBV replication in vitro (Marchini et al., 1991 ; Lee & Yates, 1992) this may not be the case in vivo. Recent work in epithelial cells shows that BHRF1 is capable of protecting the cells from death by apoptosis in serum-starved conditions and can also delay commitment of the cells to the apoptotic process of terminal differentiation (Dawson et al., 1995) . This effect may be important in promoting the survival of EBV-infected epithelial cells that enter into the virus productive cycle so that full virus replication and maturation can occur. This hypothesis is supported by the observation that in normal stratified squamous epithelium Bcl-2 expression is found in the basal cell layer but is down-regulated in suprabasal cells as part of the apoptotic process resulting in terminal differentiation (Hockenbury et al., 1991) . Thus, we would argue that BHRF1 expression in Bcl-2-negative suprabasal epithelial cells or in Bcl-2-negative F. Khanim and others F. Khanim and others B lymphocytes may be an important requirement for the efficient production and release of mature EBV virions, hence explaining the degree of sequence and functional conservation over the BHRF1 ORF observed in this study. The finding that like EBV and herpesvirus saimiri, the recently discovered Kaposi's sarcoma herpesvirus also carries a functional Bcl-2 homologue (Sarid et al., 1997) , further emphasizes the importance of these anti-apoptotic proteins in the life cycle of gammaherpesviruses.
